SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    DeNardo GL, O'Donnell RT, Oldham, RK, DeNardo SJ. A revolution in the treatment of non-Hodgkin's lymphoma. Cancer Biother Radiopharm 1998;13: 31223.
  • 2
    Delaloye AB. Radioimmunoimaging and radioimmunothereapy: will these be routine procedures? Semin Nucl Med 2000; 30: 18694.
  • 3
    Yose JM, Wahl RL, Saleh M, Rohatiner AZ, Knox SJ, Radford JA, et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphoma. J Clin Oncol 2000; 18: 131623.
  • 4
    Johnson TA, Press OW. Therapy of B-cell lymphomas with monoclonal antibodies and radioimmunoconjugates: the Seattle experience. Ann Hematol 2000; 79: 17582.
  • 5
    Wittig TE, White CA, Wiseman GA, Gordon LI, Emmanouilides C, Raubitschek A, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3793803.
  • 6
    DeNardo GL, O'Donnell RT, Rose LM, Mirick GR, Kroger LA, DeNardo SJ. Milestones in the development of Lym-1 therapy. Hybridoma 1999; 18: 111.
  • 7
    O'Donnell RT, DeNardo GL, Kukis DL, Lamborn K, Shen S, Yuan A, et al. A clinical trial of radioimmunotherapy with 67Cu-2IT-BAT-Lym-1 for non-Hodgkin's lymphoma. J Nucl Med 1999; 40: 201420.
  • 8
    Yose JM, Colcher D, Gobar L, Bierman PJ, Augustine S, Tempero M, et al. Phase I/II trial of multiple dose 131iodine-Mab LL2 (CD22) in patients with recurrent non-Hodgkin's lymphoma. Leuk Lymphoma 2000; 38: 91101.
  • 9
    Linden O, Tennvallli J, Cavallli-Stahl E, Lindner KJ, Darte L, Ohlsson T, et al. A phase I/II trial with Y-90 hLL2 in recurrent B-cell lymphomas: preliminary results. Cancer Biother Radiopharm 2000; 15: 413.
  • 10
    Nuclear Regulatory Commission. Release of patients administered radioactive materials. Regulatory Guide 8.39. Washington, DC: USNRC, 1997.
  • 11
    Wahl RL, Kroll S, Zasadny KR. Patient-specific whole-body dosimetry: principles and a simplified method for clinical implementation. J Nucl Med 1998; 39: 14S20S.
  • 12
    Siegel JA. Revised Nuclear Regulatory Commission regulations for release of patients administered radioactive materials: outpatient iodine-131 anti-B1 therapy. J Nucl Med 1998; 39: 28S33S.
  • 13
    Kaminski MS, Estes J, Tuck M, Mann J, Fisher P, Kison D, et al. Iodine I-131 tositumomab therapy for previously untreated follicular lymphoma. Proc Am Soc Clin Oncol 2000; 19: 5a.
  • 14
    Croll MN, Brady LW. Intracavitary uses of colloids. Semin Nucl Med 1979; 9: 10813.